VistaGen Therapeutics, Inc. (VTGN) earnings
VTGN earnings moved a median of -0.75% by the close. Quarterly and annual VTGN reports and results, each read against the price at its own news timestamp. Back to the VTGN overview →
17 measured VTGN earnings events.
Where these VTGN earnings landedvs 17 measured VTGN earnings reactions
| Middle 50% of VTGN earnings reactions | -3.70% to +2.50% |
|---|---|
| Median reaction (to close) | -0.75% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 VTGN earnings events with a measured close landed between -3.70% and +2.50%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Vistagen Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.19% | -3.70% | |
| Form 10-K Vistagen Therapeutics, For: Mar 31 | SEC filing · Form 10-K | -3.43% | +18.97% | |
| Form 10-Q Vistagen Therapeutics, For: Dec 31 | SEC filing · Form 10-Q | -8.38% | +5.33% | |
| Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 | Press release | +2.53% | -3.45% | |
| Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 | Press release | +1.99% | -0.75% | |
| Form 10-Q Vistagen Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.72% | +7.22% | |
| Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 | Press release | +0.23% | -4.33% | |
| Form 10-K Vistagen Therapeutics, For: Mar 31 | SEC filing · Form 10-K | -3.88% | -11.21% | |
| Form 10-Q Vistagen Therapeutics, For: Dec 31 | SEC filing · Form 10-Q | -2.71% | +0.68% | |
| Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 | Press release | +0.00% | -4.33% | |
| Form 10-Q Vistagen Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.38% | +0.32% | |
| Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 | Press release | +0.00% | +0.32% | |
| Form 10-Q Vistagen Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.50% | |
| Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 | Press release | -1.24% | -1.24% | |
| Form 10-K Vistagen Therapeutics, For: Mar 31 | SEC filing · Form 10-K | +1.32% | -2.90% | |
| Form 10-Q Vistagen Therapeutics, For: Dec 31 | SEC filing · Form 10-Q | +2.16% | +5.89% | |
| Form 10-Q Vistagen Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.04% | -10.76% |
Keep exploring
More VTGN: analyst actions → · SEC filings → · VTGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
| Inovio Pharmaceuticals, Inc. (INO) | 658 | -0.29% | 43% |
| Quanterix Corporation (QTRX) | 657 | -0.21% | 46% |
| Encompass Health Corporation (EHC) | 656 | +0.01% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.